

ASH Annual Meeting, December 9-12, 2023

Presentation schedule for Winship Cancer Institute of Emory University faculty and trainees
All times listed in Pacific Time



Friday, December 8, 2023

Time	Location	Type	Session	Presenter	Title
7:00 PM-10:00 PM	Grand Ballroom, 4 (Omni San Diego)	Friday Satellite Symposia	Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma	Sagar Lonial, MD (speaker)	
7:00 AM-10:00 AM	Grand Ballroom, 4 (Omni San Diego)	Friday Satellite Symposia	Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma	Jonathon B. Cohen, MD, MS (speaker)	
4:18 PM-4:59 PM	Room 29 (San Diego Convention Center)	Scientific Workshop	Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure Program	Kirsten M. Williams, MD (moderator)	How Scientific Advances Impact Clinical Predictive Models and Recommendations

Saturday, December 9, 2023

Time	Location	Type	Session	Presenter	Title
9:30 AM-11:00 AM	Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)	Symposia	627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL	Jason T. Romancik, MD (moderator)	
10:15 AM	Room 29 (San Diego Convention Center)	Oral	113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease	Britney Hernandez	Evaluation of GBT021601 As a Therapeutic Agent to Restore Bone Marrow Health and Effective Erythropoiesis in a Sickle Mouse Model
2:00 PM-3:30 PM	Halls G-H - Blood Journals Studio	Award Ceremony	Distinguished Abstract Achievement Award Ceremony	Eudorah Vital (award recipient)	ASH Minority Graduate Student Abstract Achievement Award

4:00 PM-5:30 PM	Grand Hall C (Manchester Grand Hyatt San Diego)	Oral	627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents	Jean L. Koff, MD, MSc	LEO Consortium for Real World Evidence (CREWE): Outcomes after Second-Line Therapy in Large B-Cell Lymphoma By Treatment Era
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I	Ellen Marin, PA-C	Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	711. Cell Collection and Processing: Poster I	Po-Chih Hsu, DMD, PhD	Donor T Cell Infusions Limit Novel Immune Checkpoint Therapy in Pancreatic Cancer: Implications for Adoptive T Cell Therapy
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I	Denis Ohlstrom, MSc	Seventeen-Gene Signature Identifies AML Cells in Single Cell RNA Sequencing Data and Resolves Treatment Resistant Subtypes
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	701. Experimental Transplantation: Basic and Translational: Poster I	Yiwen Li, MS	Vasoactive Intestinal Peptide Signaling in Transplant Recipients Modulates Gut Microbiome Diversity and Regulates Graft-Versus-Host Disease
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I	Leon Bernal-Mizrachi, MD	Development of First in Class DNA-Zip Code Drug Conjugate (ZDC) in Multiple Myeloma
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I	Andrea B. Moffitt, PhD	Personalized Residual Disease Detection in Acute Myeloid Leukemia with a Multiplexed Genomic Fingerprint Predicts Patient Outcomes
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	905. Outcomes Research—Lymphoid Malignancies: Poster II	Xinyue Zhang	Health Insurance Continuity Is Associated with Stage at Diagnosis Among Children, Adolescents, and Young Adults Newly Diagnosed with Lymphoma
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	652. Multiple Myeloma: Clinical and Epidemiological: Poster I	Semaje Testamark	Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I	Madhav Dhodapkar, MBBS	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	101. Red Cells and Erythropoiesis, Excluding Iron: Poster I	Ashwin P. Patel, MD, PhD, MPH	Red Cell Rheology and Blood Viscosity in Pediatric Individuals Having Received Allogenic Hematopoietic Stem Cell Transplantation or Ex Vivo Autologous Gene Therapy for Sickle Cell Disease

5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I	Eudorah Vital	Non-Invasive Screening for Sickle Cell Disease Using Only a Smartphone Application
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	506. Bone Marrow Microenvironment: Poster I	Alejandro De Janon, MSc	Self-Supporting Human Acute Myeloid Leukemia (AML) Bone Marrow Organoids Established from Patient-Derived Xenografts Mimic the Human AML Microenvironment, with Distinct Cytokine Kinetics Correlating with Dynamic Cell Proliferation and Metabolic Shifts
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	801. Gene Therapies: Poster I	Zachary Kostamo	Evaluation of the Impact of a Naturally Occurring Beta Hemoglobin Variant, Hb G-Makassar, on Mature Red Blood Cell Function and Pathology in a Sickle Cell Disease Mouse Model
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I	Sarthak Satpathy	Simple Preservation of Single Cells (SENSE): One-Step Robust Whole Blood Cryopreservation Method Enables the Generation of High-Quality Single-Cell Immune Profiles
5:30 PM-7:30 PM	Halls G-H (San Diego Convention Center)	Poster	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I	Michelle L. Schoettler, MD	Age, Gvhd Prophylaxis, and Timing Matter in Thrombotic Microangiopathy after Hematopoietic Cell Therapy- a Secondary CIBMTR Analy
6:30 PM-8:00 PM	Marina Ballroom D (Marriott Marquis San Diego Marina)	Oral	Promoting Minorities in Hematology (PMH) Oral Presentations: Room I	Dailia B. Francis, MD, PhD	The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin Lymphomas

Sunday, December 10, 2023

Time	Location	Type	Session	Presenter	Title
9:30 AM-11:00 AM	Room 6A	Symposia	Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies	Sarwish Rafiq, PhD (moderator)	
5:30 PM	Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)	Oral	652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma	Nisha S. Joseph, MD	Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
5:30 PM	Room 33 (San Diego Convention Center)	Oral	113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans	Christopher Chambliss, PhD	Characterizing Pregnancy Outcomes in a Humanized Mouse Model of Sickle Cell Disease

6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	905. Outcomes Research—Lymphoid Malignancies: Poster II	Sharon M. Castellino, MD, MSc	Impact of Survivorship Care Plans (SCP) on Mortality in a Contemporary Cohort of Pediatric Patients Diagnosed with a Blood Cancer
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	905. Outcomes Research—Lymphoid Malignancies: Poster II	Tarun Jain	Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II	Veronica Canarte	SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster II	Brooj Abro, MD	Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II	Erica N. Evans	Radchip: A Laminin-Lined Red Blood Cell (RBC) Adhesion Device for Functional Characterization and Clinical Evaluation of Sickle RBCs at Steady-State
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II	Akshay A. Patwardhan	Comparison of Devices That Measure Sickle Red Cell Deformability
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II	Mojtaba Bakhtiari, MD	Vinpocetine Mediates Therapeutic Activity Alone and in Combination with Chemotherapy in T-Cell Acute Lymphoblastic Leukemia
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III	Kristopher A. Knight	Development of a Novel L-Asparaginase with Enhanced Properties Using Ancestral Sequence Reconstruction

Monday, December 11, 2023

Time	Location	Type	Session	Presenter	Title
2:45 PM-4:00 PM	Grand Hall B (Manchester Grand Hyatt San Diego)	Education Program	Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?	Tamara P. Miller, MD, MSCE (chair/speaker)	Adolescent and Young Adults (AYA) Versus Pediatric Patients: Survival, Risks and Barriers to Enrollment
2:45 PM-4:00 PM	Room 29 (San Diego Convention Center)	Scientific Program	Interplay of Coagulation and Complement in Transfusion Medicine	Satheesh Chonat, MD	The Role of Complement in Bystander Hemolysis

4:45 PM	Room 31 (San Diego Convention Center)	Oral	114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future	Justin J. Yoo, MD	Rheological Characteristics of Elderly Individuals with Sickle Cell Disease Compared with an Adult Sickle Cell Population
5:00 PM	Grand Hall C (Manchester Grand Hyatt San Diego)	Oral	623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy	Jonathon B. Cohen, MD, MS	Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	653. Multiple Myeloma: Prospective Therapeutic Trials: Poster III	Ajay K. Nooka, MD, MPH	A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	621. Lymphomas: Translational—Molecular and Genetic: Poster III	Dailia B. Francis, MD, PhD	The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	652. Multiple Myeloma: Clinical and Epidemiological: Poster III	Jonathan L. Kaufman, MD	Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	703. Cellular Immunotherapies: Basic and Translational: Poster III	Heather Lin	Antagonizing Vasoactive Intestinal Peptide (VIP) Receptors on CAR T Cells Improves Efficacy and Persistence
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	801. Gene Therapies: Poster III	Jennifer Okalova	Optimization of Lentiviral β-Globin Vectors in a Forward Orientation to Enhance Therapeutic Effectiveness for Sickle Cell Disease
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III	Danielle Cicka	Acute Chest Syndrome at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System
6:00 PM-8:00 PM	Halls G-H (San Diego Convention Center)	Poster	723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III	Elizabeth Stenger, MD, MSc	Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell